Clearmind Medicine Inc.'s SEC filings document foreign private issuer reports for a clinical-stage biotech developing non-hallucinogenic, neuroplastogen-derived psychedelic therapeutics. Form 6-K reports furnish press releases on CMND-100, MEAI-based Alcohol Use Disorder clinical development, European patent activity for PTSD compounds, and communications tied to FDA regulatory pathways.
The filings also record capital-structure matters, including securities purchase agreements, convertible promissory notes, conversions into common shares and amendments to financing capacity. Governance disclosures cover board composition, committee assignments and Nasdaq independence determinations, while incorporated registration statements on Form F-3 and Form S-8 connect current reports to the company's securities registration record.
Clearmind Medicine Inc. (CMND) delivered notice on October 16, 2026, to the CLA Investors for the issuance and sale of Promissory Notes with an aggregate principal amount of $2,000,000. The notes have an aggregate cash purchase price of $1,800,000, equal to 90% of principal, and the transaction is expected to close on or before October 19, 2026.
The amended securities purchase agreements provide for the issuance and sale of notes from time to time in an aggregate principal amount of up to $10,000,000.
Clearmind Medicine Inc. (CMND) announced that its 51%-owned subsidiary, Charging Robotics Ltd., launched an automated EV-charging platform for robotaxis, autonomous fleets and automated parking facilities. The platform uses resonant inductive power transfer to send electricity across an air gap without physical connectors. Its design specifications include up to 10 kW of charging power and up to 95% efficiency under specified operating conditions.
For robotaxis and fleets, a charging pad and onboard receiver are designed to support charging without plug-in connections, robotic charging arms or dedicated docking maneuvers. The platform is designed to initiate and record charging sessions automatically. Its AI-driven system monitors vehicle and charging details to allocate available power across vehicles, prioritize charging needs and reduce peak electricity demand; it also supports remote monitoring and centralized management of charging infrastructure.
Clearmind Medicine Inc. (CMND) announced publication in Japan of a patent application covering 3-MMC compositions and methods to prevent, treat or reduce dyskinesia symptoms, including combinations with N-acylethanolamines, notably PEA. The applications are part of Clearmind’s ongoing collaboration with NeuroThera Labs Inc.; the company says PEA technology is integrated into its psychedelic-derived therapeutic programs. Clearmind reports that its intellectual property portfolio consists of 19 patent families, including 32 granted patents. The company cautioned that it cannot assure a patent will issue from the pending application.
Clearmind Medicine Inc. (CMND) submitted recommendations to the U.S. Food and Drug Administration (FDA) in response to its public hearing and request for comments on the potential future therapeutic use of psychedelic drugs. The company asked FDA to consider guidance for self-administration and at-home-potential therapies, streamlined regulatory pathways, expanded clinical-trial access, and leveraging Breakthrough Designation.
Clearmind also called for research and clinical collaborations with the U.S. Department of Veterans Affairs, U.S. Department of War, and U.S. Department of Health and Human Services to help pilot safer, at-home-potential neuroplastogenic candidates for alcohol use disorder and other indications. The company says data from clinical trials at Yale University and Johns Hopkins University suggest non-hallucinogenic compounds may retain therapeutic benefits of neuroplasticity enhancement while eliminating hallucinogenic effects, potentially mitigating the need for expensive supervised dosing. Clearmind describes its portfolio as 19 patent families, including 32 granted patents.
Clearmind Medicine Inc. (CMND) will effect a 1-for-8 reverse split of its common shares, with split-adjusted trading on the Nasdaq Capital Market beginning October 5, 2026. Issued and outstanding common shares will adjust from 4,059,227 to 507,404, subject to further adjustments based on the treatment of fractional shares. No fractional shares will be issued; fractions will be rounded up to the nearest whole common share. The split will proportionately adjust the per-share exercise price and number of shares issuable under outstanding options and warrants. Authorized share capital will remain unchanged.
Clearmind Medicine Inc. (CMND) announced the U.S. publication of three patent applications covering combinations of LSD, ketamine and ibogaine with N-acylethanolamines, such as palmitoylethanolamide (PEA). The applications describe potential uses across conditions including depression, PTSD, pain and substance use disorders.
The publications expand intellectual property developed through Clearmind’s ongoing collaboration with NeuroThera Labs Inc., whose PEA technology is integrated into Clearmind’s psychedelic-derived therapeutic programs. Clearmind’s current intellectual property portfolio consists of 19 patent families, including 32 granted patents; it had previously announced a U.S. application covering MDMA and N-acylethanolamines.
Clearmind said it believes the combination approach may support therapeutic benefits at lower doses while preserving efficacy and may improve tolerability. It cautioned that it cannot assure a pending application will result in a patent or that any patent issued will be advantageous to the company.
Clearmind Medicine Inc. (CMND), a clinical-stage biopharmaceutical company focused on non-hallucinogenic psychedelic-derived neuroplastogens, reported that, following an invitation from the U.S. Food and Drug Administration, it testified at an FDA hearing on September 14, 2026 on “Considerations for Potential Future Therapeutic Use of Psychedelic Drugs.” Clearmind’s Chief of Global Impact, Mary-Elizabeth Gifford, briefed a federal panel on patient access, sharing insights from the company’s clinical trial being conducted at Yale University Medical School and Johns Hopkins University.
The company highlighted its proprietary candidate MEAI, developed for Alcohol Use Disorder, which is being evaluated in an FDA-approved clinical trial and is among a limited number of non-hallucinogenic, psychedelic-derived neuroplastogens to reach a Phase 2a clinical trial. Clearmind also noted its intellectual property position, with nineteen patent families and 32 granted patents, and emphasized its strategy to develop scalable, potentially more accessible treatments for neuropsychiatric, metabolic, and addiction disorders.
Clearmind Medicine Inc. (CMND) reports a key clinical milestone, enrolling the first patients with Alcohol Use Disorder in its ongoing CMND-100 trial, with the first two patients treated at Hadassah Medical Center in Jerusalem. This is the first administration of CMND-100 to AUD patients, following prior multi-dose evaluation in healthy participants. The study is designed to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of this non-hallucinogenic, psychedelic-derived candidate for AUD. Two paragraphs of the announcement are also incorporated by reference into several of Clearmind’s effective Form F-3 and Form S-8 registration statements.
Clearmind Medicine Inc. (CMND) reported unaudited IFRS results for the three and nine months ended July 31, 2026. The company remains pre-revenue and recorded a nine‑month net loss of $6.8 million, wider than $3.2 million a year earlier, driven mainly by higher general and administrative expenses of $5.5 million and research and development of $1.9 million. Fair value gains on warrants and investments produced nine‑month finance income of $0.6 million.
Cash and cash equivalents rose to $12.0 million, with total assets of $16.9 million and working capital of $12.8 million, supported by equity offerings and $7.9 million of new convertible note proceeds, though $8.9 million of notes were also converted into equity. The company discloses that recurring losses, negative operating cash flow of $5.8 million and an accumulated deficit of $34.7 million raise substantial doubt about its ability to continue as a going concern, and ongoing operations depend on continued access to external financing.
Subsequent to quarter-end, Clearmind agreed to convert additional Promissory Notes at $1.00 per share, reset related warrant exercise prices to $1.00, and acquired a 51% stake in Charging Robotics for $2.5 million plus a $1.5 million loan at 4% interest. The company continues its Phase I/IIa CMND‑100 clinical program for Alcohol Use Disorder, with its Data and Safety Monitoring Board repeatedly recommending continuation and advancement to later study parts. Clearmind also highlights Nasdaq listing risk from potential new minimum Market Value of Listed Securities rules, with its MVLS at approximately $3.5 million on September 8, 2026.
Clearmind Medicine Inc. (CMND), a clinical-stage biotech developing non-hallucinogenic psychedelic-derived neuroplastogens for neuropsychiatric, metabolic and addiction disorders including Alcohol Use Disorder, reports that Yale University’s IRB has approved initiation of patient recruitment for Parts B and C of its Phase I/II CMND-100 trial. This enables Clearmind to expand enrollment at Yale School of Medicine’s Department of Psychiatry, joining Johns Hopkins University School of Medicine, Tel Aviv Sourasky Medical Center and Hadassah Medical Center, which are already recruiting. Clearmind previously completed Part A of the FDA-regulated trial with 24 participants across four ascending-dose cohorts, achieving the primary endpoint of safety and tolerability with no serious adverse events, supporting continued clinical advancement of CMND-100.